&lt;p&gt;Loading Amlodipine on Diamond Nanoparticles: A Novel Drug Delivery System&lt;/p&gt;

Alawdi, Shawqi H.; Eidi, Housam; Safar, Marwa M.; Abdel-Wahhab, Mosaad A.

doi:10.2147/nsa.s232517

Cited by 15 publications

(9 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We began exploring other inhibitors, such as channel blockers, to see if other routes of uptake are possible due to the characteristics CNDs have [ 69 ]. After exploring our selected known channel blocking inhibitors, the results displayed that amlodipine, a calcium channel blocker [ 40 ], increased the fluorescence of CNDs. Previous studies completed on human umbilical vein endothelial cells (HUVEC) suggested that when a build-up of calcium occurs internally within endothelial cells, this stimulates an increase in endocytosis events [ 70 ].…”

Section: Discussionmentioning

confidence: 99%

Anti-Inflammatory Effect and Cellular Uptake Mechanism of Carbon Nanodots in in Human Microvascular Endothelial Cells

et al. 2021

View full text Add to dashboard Cite

Cardiovascular disease (CVD) has become an increasingly important topic in the field of medical research due to the steadily increasing rates of mortality caused by this disease. With recent advancements in nanotechnology, a push for new, novel treatments for CVD utilizing these new materials has begun. Carbon Nanodots (CNDs), are a new form of nanoparticles that have been coveted due to the green synthesis method, biocompatibility, fluorescent capabilities and potential anti-antioxidant properties. With much research pouring into CNDs being used as bioimaging and drug delivery tools, few studies have been completed on their anti-inflammatory potential, especially in the cardiovascular system. CVD begins initially by endothelial cell inflammation. The cause of this inflammation can come from many sources; one being tumor necrosis factor (TNF-α), which can not only trigger inflammation but prolong its existence by causing a storm of pro-inflammatory cytokines. This study investigated the ability of CNDs to attenuate TNF-α induced inflammation in human microvascular endothelial cells (HMEC-1). Results show that CNDs at non-cytotoxic concentrations reduce the expression of pro-inflammatory genes, mainly Interleukin-8 (IL-8), and interleukin 1 beta (IL-1β). The uptake of CNDs by HMEC-1s was examined. Results from the studies involving channel blockers and endocytosis disruptors suggest that uptake takes place by endocytosis. These findings provide insights on the interaction CNDs and endothelial cells undergoing TNF-α induced cellular inflammation.

show abstract

Section: Discussionmentioning

confidence: 99%

Anti-Inflammatory Effect and Cellular Uptake Mechanism of Carbon Nanodots in in Human Microvascular Endothelial Cells

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Targeted therapy with nanoparticles has been inserted into treatment modalities, from cardiovascular treatments to oncology treatments. Due to the small size of nanoparticles, they can be suitable for crossing the blood-brain barrier (BBB), specifically nanodiamonds with conjugating potential [ 33 ]. Researchers are trying to formulate a conjugation between a drug that does not cross the BBB, such as amlodipine, and nanodiamonds that do cross it [ 34 ].…”

Section: Impact Of Nanotechnology In Pancreatic Cancermentioning

confidence: 99%

Management of Pancreatic Cancer and Its Microenvironment: Potential Impact of Nano-Targeting

Perko

Mousa

2022

Cancers

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is rare and difficult to treat, making it a complicated diagnosis for every patient. These patients have a low survival rate along with a poor quality of life under current pancreatic cancer therapies that adversely affect healthy cells due to the lack of precise drug targeting. Additionally, chemoresistance and radioresistance are other key challenges in PDAC, which might be due in part to the lack of tumor-targeted delivery of sufficient levels of different chemotherapies because of their low therapeutic index. Thus, instead of leaving a trail of off-target damage when killing these cancer cells, it is best to find a way that targets them directly. More seriously, metastatic relapse often occurs after surgery, and therefore, achieving improved outcomes in the management of PDAC in the absence of strategies preventing metastasis is likely to be impossible. Nano-targeting of the tumor and its microenvironment has shown promise for treating various cancers, which might be a promising approach for PDAC. This review updates the advancements in treatment modalities for pancreatic cancer and highlights future directions that warrant further investigation to increase pancreatic patients’ overall survival.

show abstract

“…Below are some of them that have already been successfully loaded in NPs as anti-hypertensive therapy. Amlodipine into nanodiamond particles is ready to be tested in vitro, 71 liposomes enhanced lacidipine bioavailability, 72 lomerizine in nanoparticle-based carriers suppressed Ca 2+ influx in PC12 cells in response to glutamate. 73 In vitro testinnig revealed that PLGA NPs showed longer duration of felodipine release with reduced burst release compared with pure drug paralleled by a complete biocompatibility in in vivo toxicity study in albino mice.…”

Section: Reducing Intracellular Calciummentioning

confidence: 99%

<p>Innovative Therapies and Nanomedicine Applications for the Treatment of Alzheimer’s Disease: A State-of-the-Art (2017–2020)</p>

Binda¹,

Murano²,

Rivolta³

2020

IJN

View full text Add to dashboard Cite

The field of nanomedicine is constantly expanding. Since the first work dated in 1999, almost 28 thousand articles have been published, and more and more are published every year: just think that only in the last five years 20,855 have come out (source PUBMED) including original research and reviews. The goal of this review is to present the current knowledge about nanomedicine in Alzheimer's disease, a widespread neurodegenerative disorder in the over 60 population that deeply affects memory and cognition. Thus, after a brief introduction on the pathology and on the state-of-the-art research for NPs passing the BBB, special attention is placed to new targets that can enter the interest of nanoparticle designers and to new promising therapies. The authors performed a literature review limited to the last three years (2017-2020) of available studies with the intention to present only novel formulations or approaches where at least in vitro studies have been performed. This choice was made because, while limiting the sector to nanotechnology applied to Alzheimer, an organic census of all the relevant news is difficult to obtain.

show abstract

<p>Loading Amlodipine on Diamond Nanoparticles: A Novel Drug Delivery System</p>

Cited by 15 publications

References 33 publications

Anti-Inflammatory Effect and Cellular Uptake Mechanism of Carbon Nanodots in in Human Microvascular Endothelial Cells

Anti-Inflammatory Effect and Cellular Uptake Mechanism of Carbon Nanodots in in Human Microvascular Endothelial Cells

Management of Pancreatic Cancer and Its Microenvironment: Potential Impact of Nano-Targeting

<p>Innovative Therapies and Nanomedicine Applications for the Treatment of Alzheimer’s Disease: A State-of-the-Art (2017–2020)</p>

Contact Info

Product

Resources

About